# OnCo record oncomate-msi-dx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/oncomate-msi-dx/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "oncomate-msi-dx" ;
  schema:name "OncoMate MSI Dx Analysis System"@en ;
  schema:description "Promega's microsatellite instability test, approved twice: to find microsatellite-stable endometrial cancer for pembrolizumab with lenvatinib, and MSI-high solid tumours for pembrolizumab."@en ;
  schema:url <https://onco.cc/drugs/oncomate-msi-dx/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240026>, <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250046>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Nucleic acid companion diagnostic test (microsatellite instability, tumour tissue)" ;
  schema:alternateName "OncoMate MSI Dx Analysis System" ;
  onco:approval "US 2025: Companion diagnostic for pembrolizumab with lenvatinib in microsatellite-stable endometrial carcinoma", "US 2026: Companion diagnostic for pembrolizumab in MSI-high solid tumours" ;
  onco:related <https://onco.cc/biomarkers/msi-high/> ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/lenvatinib/> ;
  onco:companies <https://onco.cc/companies/promega/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/companion-diagnostic-term/> .